Brain imaging to determine the effects of sertindole in a double-blind, placebo-controlled trial in schizophrenic patients

1996 ◽  
Vol 18 (2-3) ◽  
pp. 201-202
Author(s):  
S. Potkin ◽  
J. Zborowski ◽  
J. Wu ◽  
K. Giles ◽  
R. Bera ◽  
...  
Keyword(s):  
Brain Imaging ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Schizophrenic Patients

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity

1988 ◽  
Vol 153 (2) ◽  
pp. 208-213 ◽  
Author(s):  
E. Goodall ◽  
Christine Oxtoby ◽  
Ray Richards ◽  
Gill Watkinson ◽  
David Brown ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Side Effects ◽  
Mental State ◽  
Controlled Trial ◽  
Dietary Advice ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Schizophrenic Patients ◽  
Depot Neuroleptic

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg d-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking d-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.

Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia

1993 ◽  
Vol 163 (4) ◽  
pp. 451-455 ◽  
Author(s):  
S. J. Duinkerke ◽  
P. A. Botter ◽  
A. A. I. Jansen ◽  
P. A. M. Van Dongen ◽  
A. J. Van Haaften ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Depressive Mood ◽  
Neuroleptic Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Trial Treatment ◽  
Schizophrenic Patients ◽  
Specific Symptoms

The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial. Trial treatment was added to a stable neuroleptic treatment in 33 schizophrenic patients with predominantly negative symptoms. Ritanserin reduced the negative symptoms, as measured with the SANS. The main reduction was for the items facial expression, global affective flattening, and relationships with friends and peers. Also a reduction in total BPRS score was found, which approached statistical significance. Significant reductions were observed for the BPRS items emotional withdrawal and depressive mood. Ritanserin or other drugs blocking 5-HT2 and/or 5-HT1c receptors could be important in reducing specific symptoms in schizophrenic patients.

Enhancement of Recovery from Psychiatric Illness by Methylfolate

1991 ◽  
Vol 159 (2) ◽  
pp. 271-272 ◽  
Author(s):  
Andrew Procter
Keyword(s):  
Mental Illness ◽  
Nervous System ◽  
Psychiatric Illness ◽  
Controlled Trial ◽  
Red Cell ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Outcome Scores ◽  
Schizophrenic Patients ◽  
Social Recovery

“41 (33%) of 123 patients with acute psychiatric disorders (DSM III diagnosis of major depression or schizophrenia) had borderline or definite folate deficiency (red-cell folate below 200 μg/l) and took part in a double-blind, placebo-controlled trial of methylfolate, 15 mg daily, for 6 months in addition to standard psychotropic treatment. Among both depressed and schizophrenic patients methylfolate significantly improved clinical and social recovery. The differences in outcome scores between methylfolate and placebo groups became greater with time. These findings add to the evidence implicating disturbances of methylation in the nervous system in the biology of some forms of mental illness.”

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

A randomized double blind, placebo controlled trial of a Chinese herbal preparation (CH100) in chronic Hepatitis C

2001 ◽  
Vol 120 (5) ◽  
pp. A384-A384
Author(s):  
L MOLLISON ◽  
L TOTTEN ◽  
C HOVELL ◽  
K THAYNE ◽  
C CONNELLY ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Controlled Trial ◽  
Herbal Preparation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Chinese Herbal

40: Oral Ketoconazole for Prevention of Postoperative Penile Erection, a Prospective, Randomized, Double Blind, Placebo Controlled Trial

2007 ◽  
Vol 177 (4S) ◽  
pp. 14-15
Author(s):  
Brian J. DeCastro ◽  
Jack R. Walter ◽  
Leah P. McMann ◽  
Andrew C. Peterson
Keyword(s):  
Penile Erection ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document